english.prescrire.org > Annual Prescrire Awards > The Prescrire Awards for 2023 > Prescrire Drug Awards for 2023 > Prescrire Drug Awards for 2023

The Prescrire Awards for 2023

Prescrire Drug Awards for 2023

The Prescrire Drug Awards for 2023

Le Palmarès des Médicaments This year, none of the drugs we examined represented a major therapeutic advance worthy of a  Pilule d'Or  ("Golden Pill" Award).  Only one drug made the Honours List.
The  Pilule d'Or  ("Golden Pill") is granted to drugs that represent a major therapeutic advance in a field in which no treatment was previously available. Drugs included on the Honours List constitute a clear advance for some patients compared with existing therapeutic options, albeit with limitations.

 

Palme du Médicamenty Blincyto° (blinatumomab) - Amgen
In high-risk first-relapse acute lymphoblastic leukaemia
in children

 

A notable reduction in mortality, demonstrated in two randomised comparative trials in children with high-risk first-relapse ALL, is a clear therapeutic advance that justifies blinatumomab's place on this year's Honours List.


Download the full article:

Télécharger
 FREE  "The Prescrire Awards for 2023" Prescrire Int 2024; 33 (259): 132-134. Free.

 

Back to "The Prescrire Awards for 2023"

©Prescrire April 2024
     

Filet

Enjoy full access to Prescrire International, and support independent information